Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience

@article{Kaya2000TreatmentOC,
  title={Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience},
  author={Mushin Kaya and Piet C. de Groen and Paul Angulo and David M. Nagorney and Leonard L. Gunderson and Gregory J. Gores and Michael G. Haddock and Keith D. Lindor},
  journal={American Journal of Gastroenterology},
  year={2000},
  volume={96},
  pages={1164-1169}
}
Objectives:The aims of this retrospective study were to assess the frequency with which we used different treatment modalities for patients with primary sclerosing cholangitis (PSC) and cholangiocellular carcinoma (CCA).METHODS:A total of 41 patients with known CCA complicating PSC with a median age of 49 yr (range, 27–75 yr) were identified from a group of 1009 patients (4%) with PSC seen over 10 yr at the Mayo Clinic.RESULTS:These patients received mainly five forms of treatment: 10 patients… 

Tables from this paper

Cholangiocarcinoma in Young Individuals With and Without Primary Sclerosing Cholangitis

The youth group of cholangiocarcinoma plus PSC seems to have a higher prevalence of Crohn's disease whereas the prognosis in youth seems to be similarly poor as described in older patients with cholangsiocARCinoma.

Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation

A high proportion of cholangiocarcinoma cases is diagnosed within the first year after diagnosis of PSC, and a long history of inflammatory bowel disease is a risk factor for CC development.

Secondary Sclerosing Cholangitis: A Comparison to Primary Sclerosing Cholangitis

The natural history of secondary sclerosing cholangitis is characterized by a shortened life expectancy, and when the long-term outcome of SSC patients was compared to matched PSC controls, the S SC patients had a poorer outcome.

Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study.

Incidence, Diagnosis, and Therapy of Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis

If tumors are small or incidental findings, liver transplantation leads to a 3- to 5-year survival rate of 35%.

Surgical treatment of primary biliary cirrhosis and primary sclerosing cholangitis

It is concluded that liver transplantation represents a safe and beneficial therapy for patients with end-stage PBC, and Cirrhotic patients with PSC also benefit from OLT, with an outcome comparable to that of liver cirrhosis of other etiologies.

Primary sclerosing cholangitis: role of extrahepatic biliary resection.

Biliary Stent Therapy for Dominant Strictures in Patients Affected by Primary Sclerosing Cholangitis

The aim of this article is to review the diagnostic and therapeutic strategies for patients affected by PSC and DS with specific emphasis on the outcomes of patients treated with temporary stents.

A Review and Update on Cholangiocarcinoma

This review discusses epidemiology, etiologic factors, molecular pathogenesis, diagnosis, staging, and treatment of cholangiocarcinoma, with particular focus on recent studies into the cellular and molecular pathogenic of the disease, recent chemotherapy trials, and newer methods of staging and screening.
...

References

SHOWING 1-10 OF 32 REFERENCES

Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.

Liver transplantation provides excellent patient and graft survival rates for patients affected with PSC independent of pretransplant biliary tract surgery, however, known CCA or common duct frozen section biopsy specimen or both showing CCA are associated with poor recipient survival, and OLT should be proscribed in these cases.

Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation

Early timing of transplantation in patients with PSC is suggested to prevent formation of biliary malignancies, and regular scoring of patients with the Mayo Model risk score should be taken into consideration at scores above 4.4.

"Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention.

Unresected cholangiocarcinoma is a rapidly fatal process, but early intervention affects the course of the disease and likely prolongs patient survival, according to multivariate analysis of all hospitalized patients.

Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.

Patients with PSC have a substantially decreased survival, which is most pronounced among patients without IBD, and the risk of cholangiocarcinoma is highest among patients with a diagnosis of inflammatory bowel disease.

Long‐term results of patients undergoing liver transplantation for primary sclerosing cholangitis

The data show that liver transplantation provides excellent long‐term patient and graft survival for patients with end‐stage PSC, and patients with associated inflammatory bowel disease did not adversely impact patient outcome posttransplantation.

Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Cholangiocarcinoma is best classified into three broad groups: 1) intrahepatic, 2) perihilar, and 3) distal tumors, which correlate with anatomic distribution and imply preferred treatment.

Cholangiocarcinoma complicating primary sclerosing cholangitis.

There is a clear need for heightened clinical awareness, methods for earlier detection, and effective therapy for patients with cholangiocarcinoma complicating PSC.

A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.

BACKGROUND AND AIMS: Radiotherapy has been reported to be of benefit in prolonging the survival of patients with cholangiocarcinoma. This study examined whether radiotherapy in addition to endoscopic

Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances.

The frequent occurrence of bile duct carcinoma as a complication of PSC in this group of patients indicates that PSC has a strong tendency to undergo malignant degeneration.